Background: YKL-40, a chitinase-like cartilage glycoprotein, has recently shown its potential as a marker for sarcoidosis. Methods: This study aimed to assess whether YKL-40 at presentation may predict the course of sarcoidosis over a 4-year follow-up period and to investigate whether polymorphisms in the chitinase 3-like 1 (CHI3L1) gene might influence serum YKL-40 levels in sarcoidosis patients (n ¼ 63) and controls (n ¼ 333). Results: Patients had significantly higher (mean, 95% CI) serum YKL-40 levels (181.3 ng/ml, 50.7-648.1) compared to controls (36.6 ng/ml, po0.0001. Serum YKL-40 was elevated in 79% of the patients and was inversely correlated with DLco at presentation (r 2 ¼ À0:27, p ¼ 0:03), but not after 2-4 years of follow-up (r 2 ¼ À0:16, p ¼ 0:27). Serum YKL-40 levels in controls were dependent on the CHI3L1 À329 G/A polymorphism (mean, 95% CI): GG (n ¼ 213) 48.3 ng/ml, 41.7-56.0; GA (n ¼ 101) 31.2 ng/ml, 26.6-36.3; AA (n ¼ 17) 17.8 ng/ml, 13.6-23.4, po0.0001. In patients, this effect was not observed. Conclusions: YKL-40 may be used as a sarcoidosis disease marker, but it is unsuitable as a marker to predict the course of the disease. The CHI3L1 À329 G/A polymorphism contributes to inter-individual variations of YKL-40 levels, but does not influence sarcoidosis disease susceptibility or severity. .net (J.M.M. van den Bosch). (2007) 101, 1563-1571 Ã The SNP loci were identified using accession numbers according to the SNP database at: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?db=snp (accessed July 2005).
Background
Sarcoidosis is a systemic disease of unknown cause and is characterized by the presence of noncaseating granulomas in one or multiple organs. 1 The majority of patients have pulmonary involvement and although most undergo spontaneous remission, about 10-15% of the cases progress insidiously towards pulmonary fibrosis. 2 Fibrosis of the lung parenchyma is marked by excessive extra-cellular matrix deposition which can lead to end-stage fibrosis with honeycombing of the lungs. This sequela is associated with loss of lung capacity and has a poor prognosis with high mortality. 3 It is challenging to find reliable sarcoidosis disease markers that are capable of predicting the course of the disease. The human cartilage glycoprotein-39, or YKL-40 (its name derived from the first three N-terminal amino acids and from its molecular weight of 40 kDa) has recently shown its potential merit as a marker for sarcoidosis. 4 Beside the reported overall increase of serum YKL-40 levels in sarcoidosis patients compared to controls, pulmonary carbon monoxide diffusion (DLco) was found to be inversely correlated with serum YKL-40 levels. 4 The authors of this study concluded that YKL-40 may serve as a marker for disease activity as well as fibrosis in sarcoidosis patients.
In addition to sarcoidosis, serum YKL-40 is also elevated in systemic sclerosis, 5, 6 rheumatoid arthritis, 7-9 liver fibrosis, 10, 11 inflammatory bowel disease, 12 and type 2 diabetes. 13 Moreover, elevated YKL-40 has been reported to predict shorter survival in cancer patients. [14] [15] [16] [17] [18] [19] YKL-40 is a member of the chitinase family and is secreted by articular chondrocytes and synovial cells 20 as well as by disease-associated cells including cancer 21, 22 and inflammatory cells. 4, 23, 24 Unlike its other family members, YKL-40 does not exert chitinase activity. 20 Instead, a single amino acid substitution causes YKL-40 to replace its potential chitinase property to the ability to bind lectin. 25 Although its precise function has not yet been elucidated, the biological properties of YKL-40 suggest that it plays a role in tissue inflammation, remodeling, and the development of fibrosis. [26] [27] [28] In fact, in vitro studies by Recklies et al. 29 have shown that YKL-40 is a potent growth factor for connective tissue cells including human fibroblasts.
Another chitinase that has been studied as a potential marker for sarcoidosis is chitotriosidase. 30 Contrary to YKL-40, this protein does exert chitinase activity and is also highly expressed by activated macrophages. 25 Chitotriosidase has even shown to be higher in advanced radiographic stages of the sarcoidosis. 30 The precise role of chitotriosidase in the pathogenesis of sarcoidosis has, like YKL- 40 , not yet been identified.
Single nucleotide polymorphisms (SNPs) of genes that are involved in the pathogenesis of sarcoidosis have shown to contribute to the vastly different patterns with which this disease can evolve. 31 SNPs may alter the nature of a protein and is reflected by altered physiologic properties or changed expression levels. Functional polymorphisms present in proteins which are used as disease markers may complicate the interpretation of differential protein levels in both healthy and affected individuals. In the ACE gene, for instance, an insertion/deletion (I/D) polymorphism in intron 16 is known to exhibit gross differences of baseline expression levels based on the genotype of the coding gene. 32 As a consequence, the precision needed to differentiate between normal and deviating levels may be compromised. 33 The YKL-40 coding chitinase 3-like 1 (CHI3L1) gene also bears a large number of polymorphic sites, some of which are potentially functional. The aim of this study was to investigate whether SNPs in the CHI3L1 gene may influence serum YKL-40 levels in Dutch Caucasian sarcoidosis patients and healthy controls. The biallelic polymorphisms which we evaluated included two that are present in the promoter region, three in different intron/exon boundaries and one SNP in exon 5 that causes an amino acid substitution (Arg145Gly).
We also tested the hypothesis by Johansen et al. 4 that YKL-40 levels may predict the course of pulmonary sarcoidosis by comparing the YKL-40 levels at presentation with radiographic evolution and pulmonary function tests over a 4-year follow-up period.
Methods

Healthy volunteers and patients
Venous blood samples were obtained from 333 ostensibly healthy employees of the St Antonius Hospital; 214 women (39712.0 years) and 119 men (42710.2 years). By completing a questionnaire, relevant background information was provided by these volunteers which included medication, ethnicity, and hereditary diseases. The over-representation of women who participated in this study is explained by the predominantly female workforce at this hospital. Fifty-five individuals (33 women and 22 men) smoked for at least 5 pack-years. Ethnicity of both parents was used as the criterion for assuming Dutch Caucasian ethnicity of the subject. Exclusion criteria included known pulmonary disease and non-Dutch Caucasian ethnicity. The medical ethical committee of this hospital approved the study conducted and all subjects gave formal written consent.
Seventy-five unrelated Dutch Caucasian sarcoidosis patients (44 males/31 females; age at diagnosis (years)7SD/ range: 39711.2 years/17-71) were included in this retrospective study. The diagnosis of sarcoidosis was established in 50 patients when clinical findings were supported by histological evidence and after exclusion of other known causes of granulomatosis in accordance with the consensus of the ATS/ERS/WASOG statement on sarcoidosis. 34 Chest radiographs were assessed to determine disease severity using standard radiographic staging for sarcoidosis, classified according to the Scadding criteria. 34 One patient presented with radiographic stage 0, 20 patients presented with stage I, 11 patients presented with stage II, 15 patients presented with stage III, and three patients presented with stage IV disease. In 25 patients, the diagnosis was made without biopsy proof because these patients presented with the classic symptoms of Löfgren's syndrome, namely fever, erythema nodosum, arthralgia, and bilateral hilar lymphadenopathy.
No prior treatment for sarcoidosis was given prior to presentation. After presentation, individuals who were treated with corticosteroids for at least 3 months during ARTICLE IN PRESS the 4-year follow-up period, were considered as having received treatment (n ¼ 28). No other treatment regimens had been used in the study group.
Radiographic evolution over a 4-year follow-up period was categorized as follows: acute/self-remitting (normalization or improvement towards stage I) (n ¼ 25), chronic (persistent stage II/III or progression towards this stage) (n ¼ 16), and fibrosis (stable stage IV or progressive towards this stage) (n ¼ 9), and patients with Löfgren's syndrome (n ¼ 25). Except for one, all patients with Löfgren's disease had received radiographic follow-up. These patients had normalized chest radiography after 2 or 4 years following presentation, except for one patient, who remained at radiographic stage I after 4 years.
Pulmonary function tests were performed at presentation and upon 2, and 4 years following diagnosis. Vital capacity (inspiratory) (VC), forced expiratory volume in 1 s (FEV 1 ), and carbon monoxide diffusing lung capacity (DLco) were used to assess the presence of lung function impairment at presentation and follow-up of disease. All lung function parameters are expressed as percent predicted values. VC and FEV 1 were calculated from volumes in liters and adjusted to BTPS (body temperature, ambient pressure, saturated with water vapor) in accordance with the ERS recommendations. 35 The medical ethical committee of the St. Antonius Hospital approved the study conducted and all subjects gave formal written consent.
Serum YKL-40 measurements
Serum YKL-40 was measured with an enzyme-linked immunosorbent assay kit (Metra YKL-40, Quidel Corporation, San Diego, CA, USA), in accordance with the manufacturer's instructions. 36 All samples were run in duplicate and mean values were used for analysis. The mean intra-assay coefficient of variance (CV) was calculated from two control samples (low: 40 ng/l and high: 150 ng/l) that were both measured in duplicate on 5 different days. The CV was 3.5%.
Serum YKL-40 levels were measured in patients only at presentation of sarcoidosis.
Genotyping
Biallelic SNPs were determined using sequence-specific primers) and polymerase chain reaction (PCR).
The identification numbers of the SNP loci and the sequences of SNP-specific primers with their complementary consensus primers are shown in Table 1 . The PCR conditions were as previously described. 37 The final primer concentrations used were 7.6 ng/ml. DNA was available from 63 patients.
Statistical analysis
The statistical evaluation of our data was performed using SPSS 11 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism v. 4 (Graphpad Software, Inc., San Diego, CA, USA) software packages. Statistical analyses of SNP and haplotype frequency distributions were performed using chi-square contingency table analysis with the appropriate number of degrees of freedom. Fisher's exact test was used if expected cell frequencies were lower than 5. Adjustment for multiple tests was made by multiplying the p-value by the number of SNPs being investigated (Bonferroni method). Genotype frequencies were tested for Hardy-Weinberg equilibrium. Haplotypes were determined using Phase, version 2 (Mac OS X). 38, 39 YKL-40 values were ln-transformed before analysis, since these were ln-normal distributed; antilog geometric mean values are denoted as mean. Analysis of variance was performed and the portion of the serum YKL-40 level variance, explained by the CHI3L1 genotype and other factors, was estimated. Fixed factors in the ANOVA model were gender, smoking history, and the CHI3L1 genotype. Age was included as a covariate. The ANOVA was followed by the appropriate post-testing for comparisons between groups. Correlation between variables was assessed with Spearman's rho.
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The sensitivity and the specificity were established using the receiver operating characteristic (ROC) curve by plotting the sensitivity against the reverse specificity (1Àspecificity) at each value.
Statistical significance was denoted by a value of po0.05 for all tests performed.
Results
Serum YKL-40 levels in controls Mean (median) serum YKL-40 in controls was 36.6 (37.3) ng/ ml. The calculated reference range (mean71.96 Â SD) was: 11.9-110.0 ng/ml.
Age correlated with YKL-40 levels (r 2 ¼ 0:23, po0.0001) and explained 5% of the variation. Smoking history or gender did not significantly influence serum YKL-40 levels (data not shown).
Serum YKL-40 levels in patients
Sarcoidosis patients had significantly higher (mean (median), 95% CI) serum YKL-40 levels (181.3 (210.0) ng/ml, 50.7-648.1) compared to controls, po0.0001. Based on the reference interval of controls, 59 sarcoidosis patients (79%) showed serum YKL-40 levels that exceeded the upper reference limit.
An ROC curve revealed that at the value of 72.0 ng/ml, serum YKL-40 had a sensitivity of 90% and a specificity of 72%. The area under the curve was 0.953 ( Fig. 1 ).
YKL-40 levels and clinical parameters in sarcoidosis patients
Radiographic staging at presentation or radiographic evolution were not associated with YKL-40 levels (data not shown). Since treatment in a number of patients (n ¼ 28) was not given at the time of presentation, the influence of treatment on serum YKL-40 levels could not be determined for that time point. However, YKL-40 levels at presentation (242.3 ng/ml, 95% CI: 195.7-289.0) were not different between those patients who received subsequent treatment within the 4-year follow-up period and those who did not (232.6 ng/ml, 95% CI: 184.3-280.9).
Serum YKL-40 showed an inverse correlation with DLco (%) at presentation (r 2 ¼ À0:27, p ¼ 0:03), but not with DLco measured at 2-4 years (r 2 ¼ À0:16, p ¼ 0:27). Sarcoidosis patients who had DLco levels below the mean (85%) had significantly higher mean serum YKL-40 levels than those with DLco values equal to or above the mean: 259.8 ng/ml, 95% CI: 200.3-317.3 versus 170.7 ng/ml, 95% CI: 134.3-210.6, p ¼ 0:004 (Fig. 2) .
Neither FEV 1 nor VC (both measured at presentation or after 2-4 years) correlated with serum YKL-40 levels (data not shown). Table 2 summarizes the results of CHI3L1 genotype and allele carrier frequencies in the Dutch sarcoidosis patients and controls. No deviation from Hardy-Weinberg equilibrium was observed for any of the groups studied. No differences were found for genotype, allele or allele carrier frequencies between sarcoidosis patients and controls. None of the polymorphisms were associated with any of the clinical parameters including lung function and radiographic staging (data not shown). Four major haplotypes with six polymorphic sites in the CHI3L1 gene were established (Table 3 ). There was no difference in haplotype frequencies between sarcoidosis patients and controls.
CHI3L1 single nucleotide polymorphisms
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Association between genetic variants of CHI3L1 and serum YKL-40 levels in controls and sarcoidosis patients
Each SNP in the CHI3L1 gene was analyzed for association with serum YKL-40 levels. All six polymorphic sites were found to influence serum YKL-40 levels in a gene-dosedependent manner. Figure 3A illustrates the effect of SNP À329 G/A on serum YKL-40 levels in healthy controls. To test whether the variation in YKL-40 levels was influenced independently by the individual SNPs or by linkage disequilibrium between them, a multivariate analysis was performed. In this model, which was adapted from the method used by Zhu et al., 40 the SNP that explained most of the variation of serum YKL-40 levels was selected as a covariate to identify the influence of the remaining SNPs (analyzed separately). The À329 G/A polymorphism showed the highest variance: 23%, po0.0001). Also, age was included as a covariate and gender and smoking history were included as fixed factors. The analysis revealed that the correction of serum YKL-40 levels by the À329 G/A polymorphism negated the influence of the other polymorphisms on serum YKL-40 levels ( Table 4 ). The isolated effect of the À329 G/A SNP was also illustrated by determining haplotype-specific serum YKL-40 levels. When heterozygous carriers of either of the haplotypes in combination with haplotype 1 were compared with each other in terms of (mean) serum YKL-40 levels, the only significant differences were those observed between haplotypes that differed from the À329 allele: haplotype carrier 1+1 (43.8 ng/ml) versus 1+2 (28.8 ng/ml), po0.0001; haplotype carrier 1+2 (28.8 ng/ml) versus 1+3 (49.4 ng/ml), po0.0001; haplotype carrier 1+2 (28.8 ng/ml) versus 1+4 (44.7 ng/ml), po0.05; haplotype carrier 1+2 (28.8 ng/ml) versus 1+5 (60.3 ng/ml), po0.01; haplotype carrier 1+5 (60.3 ng/ml) versus 1+6 (22.3 ng/ml), po0.05.
The À329 G/A polymorphism did not appear to significantly influence serum YKL-40 levels in sarcoidosis patients (Fig. 3B ) despite the trend towards lower mean values associated with the presence of the A allele: genotype AG (153.2 ng/ml) compared to GG (192.7 ng/ml), p ¼ 0:16, nor did correcting the effect of the À329 G/A SNP for smoking, gender, and age in a multivariate analysis reveal a genotypedependent influence on serum YKL-40 levels (data not shown). Age correlated significantly with serum YKL-40 in a Ã Corrected for smoking history, gender, and age. y SNP À329 G/A was used as a covariate to determine the effects of the remaining five SNPs on serum YKL-40 levels. Smoking history, gender and age were also included as fixed factor or covariate. Mean YKL-40 and 95% CI were calculated from log-transformed data. similar pattern as that which was observed in the control population (r 2 ¼ 0:24, p ¼ 0:04). No association was found between the remaining five polymorphisms and serum YKL-40 levels in sarcoidosis patients (data not shown).
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The observed association between DLco and serum YKL-40 levels was not attributed to the À329 G/A genotype distribution between patients below and equal/above the mean DLco (85%) (data not shown).
Age and genotype-specific reference intervals
In order to calculate the expected serum YKL-40 levels of an individual that is corrected for age and the À329 G/A genotype, the following formulas were deduced from the multivariate analysis: 
Discussion
This study supports the merits of serum YKL-40 as a disease marker for sarcoidosis, as previously shown by Johansen et al. 4 Serum YKL-40 levels were found to be elevated in 79% of the sarcoidosis patients. However, the low specificity and the previously described elevations of YKL-40 associated with various other diseases 5-12 may limit the use of YKL-40 as a diagnostic marker for sarcoidosis.
Serum YKL-40 levels were found to increase with age, although the extent to which serum YKL-40 was elevated in sarcoidosis patients was too high to allow age to influence the accuracy of serum YKL-40 as a sarcoidosis marker.
The inverse correlation between serum YKL-40 levels and DLco seemed to suggest that YKL-40 is related to the development of pulmonary fibrosis. This notion was also reported by Johansen et al. 4 and is well supported by the fact that YKL-40 is a strong growth factor for human fibroblasts. 29 However, since the development of pulmonary fibrosis is usually irreversible, 3 the lack of correlation between DLco measured at later time points during followup and serum YKL-40 levels measured at presentation does therefore suggest against the presence of fibrosis. Vascular involvement in pulmonary sarcoidosis is often seen 41 and is, like fibrosis, often reflected by a decreased DLco. 42 The observed correlation between YKL-40 and DLco may therefore be attributed to events that remain yet to be identified. Contrary to what Johansen et al. 4 have described, YKL-40 levels above the median were not associated with decreased DLco values. Instead, sarcoidosis patients with DLco values below the mean had higher YKL-40 levels. An observation similar to ours has been reported in systemic sclerosis patients with pulmonary fibrosis by chest X-ray. In this report, patients with decreased DLco showed higher serum YKL-40 levels in serum. 5 Although our findings emerged from assessing a larger group of patients of whom DLco as well as YKL-40 data were available (n ¼ 44 versus n ¼ 27), even larger groups should be used to resolve the inconsistent findings between Johansen's and our study.
This study is the first to describe a genotypic influence of the CHI3L1 À329 G/A polymorphism on serum YKL-40 levels in healthy individuals. This polymorphism was shown to explain as much as 23% of the variation in serum YKL-40 levels. In the sarcoidosis patients, the genotype-dependent effect of the À329 G/A polymorphism was not observed. Possibly, in a disease state, pathologic factors involved in sarcoidosis which contribute to an increase of YKL-40 levels may over-rule the variance attributed to the À329 G/A polymorphism in CHL3L2. Just as what was argued for age, there may not be a diagnostic merit in correcting serum YKL-40 levels for the À329 G/A genotype.
To test the hypothesis that the À329 G/A genotype might predispose to pulmonary fibrosis, significantly more patients with fibrotic involvement as well as complete lung function, radiographic data, and genotype are required.
Using an online tool to check for functional motifs at position À329 did not reveal any changes in the motif found for the wild-type nucleotide (http://motif.genome.jp/). The actual position of the SNP is therefore unlikely to be the quantitative trait locus (QTL) itself. Instead, it may be in linkage with another, yet to be identified QTL. Like ACE, in which the I/D polymorphism explains as much as 50% of the variance of ACE activity through linkage with the actual QTL, 32, 43 additional sequencing of the promoter region of the CHI3L1 gene may indicate a site that is responsible for an even higher variation of YKL-40 levels.
Conclusion
This study shows that YKL-40 can be used as a disease marker for sarcoidosis with the stipulation that other diseases associated with elevated serum YKL-40 levels can be excluded upon assessment and during follow-up. Serum YKL-40 levels could not predict the course of pulmonary disease phenotypes according to radiographic evolution over a 4-year follow-up period. YKL-40 may be a useful marker in combination with clinical parameters such as chest X-ray and lung function and could aid in the follow-up monitoring of disease activity. Furthermore, we delivered in vivo evidence that the CHI3L1 À329 G/A polymorphism contributes to inter-individual variations of YKL-40 levels. However, the CHI3L1 À329 G/A polymorphism does not seem to influence sarcoidosis disease susceptibility or severity.
The observed influence of CHI3L1 À329 G/A on serum YKL-40 levels may also be of interest for investigations involving YKL-40 in other diseases.
